U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07745621) titled 'Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia' on June 22.
Brief Summary: The study objective is to evaluate the safety and feasibility of the Vivifi device to treat symptomatic, benign prostatic hyperplasia (BPH).
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Benign Prostatic Hyperplasia
Intervention:
DEVICE: Minimally invasive percutaneous ablation
Percutaneous ablation will be used to modify the vascular supply to the prostate via a minimally invasive scrotal approach
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vivifi Medical
Published by HT Digital Content Se...